Abstract: Provided herein are antibodies, such as immunoglobulins Y (IgY) antibodies that inhibit beta-lactamase activity, e.g., TEM-1 beta-lactamase, as well as related compositions and methods of use thereof to treat infections by lactam-based antibiotic bacteria that produce beta-lactamase that can degrade antibiotics.

Abstract: Recombinant Shigella minimal invasion plasmid constructs pRISM and pRISM-G and a method of inducing an immune response to Shigella in a subject, the method comprising administering the composition to the subject in an amount sufficient to induce an immune response to Shigella in the subject.

Abstract: The present disclosure relates to immunogenic compositions comprising at least one Yersinia pestis (Y. pestis) antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against Y. pestis in a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.

Abstract: Methods for detecting and/or measuring the level of sodium-dependent multivitamin transporter (SMVT) in a biological sample. The methods include the steps of: (a) contacting the biological sample with a PERV-B.RBD ligand, a variant and/or a fragment thereof; and, detecting and/or measuring the binding of the PERV-B.RBD ligand, variant and/or fragment thereof to SMVT.

Abstract: The present invention generally relates to therapeutic compositions and methods for treating cancer patients. The compositions and methods can increase efficacy of an anti-cancer therapy, or treat, prevent, or inhibit an oncology-treatment induced condition (OTIC) induced by an anti-cancer therapy. The therapeutic compositions comprise microbial compositions and, optionally, an anti-cancer therapeutic agent. The methods comprise administering a therapeutic composition comprising a microbial composition and administering an anti-cancer therapy.

Abstract: Provided herein are methods and compositions for treating and preventing inflammatory bowel disease.

Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.

Abstract: Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, ?-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject are provided.

Abstract: A method involves recovery an extracellular vesicle from an extracellular vesicle-containing sample. Such a method of recovering the extracellular vesicle may include separating the extracellular vesicle from the extracellular vesicle-containing sample in the presence of a polymer.

Abstract: Compositions for preventing or decreasing cryptosporidiosis in animals are disclosed herein. The compositions include sources of hydrogen peroxide and are fed to animals. The animals may be neonatal calves and the cryptosporidiosis may be caused by Cryptosporidium parvum. Methods of preventing or decreasing cryptosporidiosis in animals by feeding the hydrogen peroxide-generating compositions to the animals are also disclosed. Some disclosed methods reduce the number of Cryptosporidium oocysts shed by an infected animal or reduce the infectivity of Cryptosporidium oocysts shed by an infected animal. Some methods include feeding the hydrogen peroxide-generating compositions to animals ultimately afflicted with cryptosporidiosis, and the animals gain weight despite the infection.

Abstract: A synbiotic preparation may include at least one probiotic strain and at least one amino acid or derivative thereof selected from glutamine, glutamic acid or salts thereof, conjugated glutamine, or oligopeptides of 2-10 amino acid units in length, wherein the amino acid units may be natural amino acids, and at least one amino acid unit being a glutamine or glutamic acid unit.

Abstract: The present invention relates to an immunogenic polypeptide, a nucleic acid encoding the same, a pharmaceutical composition comprising the same and the immunogenic polypeptide, nucleic acid or pharmaceutical composition for use as a medicament, particularly a vaccine, or for use in a method of treating or preventing a Borrelia infection.

Abstract: The present invention relates to a medium composition for culturing Faecalibacterium prausnitzii composed of vegetable peptone, yeast extract, a phosphate compound, a carbonate compound, cyanocobalamin (B12), L-cysteine, ammonium acetate, and maltose, and a method of mass-culturing Faecalibacterium prausnitzii using the medium composition. When the medium composition and the method for culturing Faecalibacterium prausnitzii according to the present invention are used, high-density culture and mass production of strains of Faecalibacterium prausnitzii phylogroup II are possible. In addition, when Faecalibacterium prausnitzii is mass-cultured in the medium composition free of animal components, it may be cultured at high density even in high-concentration anaerobic nitrogen gas, and thus it is possible to provide a culture method which is more economical and suitable for industrialization.

Abstract: Gut microbes to provide a preventive or therapeutic effect on infectious diseases caused by pathogenic microorganisms and uses thereof are discussed. The gut microbes resistant are characterized in that they are selected from the group consisting of Oribacterium species JBO3-101 (accession number KACC 81250BP) and Ruminococcus species JBR5-501 (accession number KACC 81249BP). The gut microbes according to the present disclosure have the effect of rendering the host resistant to infectious diseases caused by pathogenic microorganisms when the microbes are ingested.

Abstract: Novel methods for exporting target proteins from the cytosol to the extracellular surface of bacterial cells are provided. The methods are useful in that they permit the preparation of vaccines for the prevention of bacterial infectious diseases.

Abstract: Microorganisms for lowering blood ammonia level and composition for protecting neuronal cells containing the same, particularly relates to microbes or a symbiotic pair that has a neuroprotective function by lowering blood ammonia levels or reducing ammonia levels in the body and composition for protecting neuronal cells comprising the microbes. The microorganisms having a neuroprotective function by lowering the blood ammonia level can be selected from the group that include, but not limited to, a Lactobacillus sp. strain and a Streptococcus sp. strain. The ammonia removal strains and the composition have a neuroprotective effect by their excellent ability to remove neurotoxic ammonia, and thus can be widely used as a preventive or therapeutic agent for hyperammonemia and neurological diseases caused thereby.

Abstract: The result of orally administering saliva derived from a Crohn's disease patient or an ulcerative colitis patient to germ-free mice has revealed that Th1 cells markedly increased in the colons. Further, from the bacterial microbiota in the intestines of the mice in which such an increase in Th1 cells were observed, bacteria have been successfully isolated which caused strong Th1 cell induction in the colon upon intestinal colonization.

Abstract: Provided is an alga belonging to Cyanidiophyceae having a diploid cell and a haploid cell form. Also provided is a nutrient composition containing an alga belonging to Cyanidiophyceae or an extract thereof.

Abstract: The present invention relates to a composition for preventing, alleviating or treating liver injury, for example, nonalcoholic fatty liver, and more specifically, it relates to a composition for preventing or treating liver injury comprising a Ruminococcus spp. strain.

Abstract: The invention relates to antigenic polypeptides derived from a naturally occurring R. microplus protein, and nucleic acids encoding such polypeptides. The polypeptides elicit an immune response which, in turn, produces detrimental effects in R. microplus feeding on vaccinated cattle. Thus, the present disclosure provides novel vaccines to protect cattle from R. microplus infestation.